- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
Related Products
|
CD79b Antibody IGB/3170R / B-Cell Receptor CD79b Monoclonal Antibody targets CD79b, a transmembrane signaling protein encoded by the CD79B gene. Also known as B29 or Ig-beta, CD79b is an essential component of the B-cell antigen receptor (BCR) complex, which mediates antigen recognition and intracellular signaling in B lymphocytes. CD79b associates with CD79a (Ig-alpha) to form a heterodimer that interacts with membrane-bound immunoglobulins, including IgM and IgD. This association is required for efficient transport of the receptor complex to the cell surface and for the initiation of signaling following antigen engagement.
CD79b is a member of the immunoglobulin superfamily and contains an extracellular immunoglobulin-like domain, a transmembrane region, and a cytoplasmic signaling tail. Its cytoplasmic region contains an immunoreceptor tyrosine-based activation motif (ITAM), which becomes phosphorylated following BCR engagement. Phosphorylated ITAM sequences recruit signaling proteins, including spleen tyrosine kinase (SYK), initiating downstream pathways involving phospholipase C gamma 2 (PLCG2), phosphoinositide 3-kinase (PI3K), and mitogen-activated protein kinases. These signaling events regulate calcium mobilization, transcriptional responses, and cellular processes required for B-cell activation and survival.
CD79b participates in both antigen-dependent and tonic BCR signaling, supporting B-cell development, maturation, and maintenance. The CD79a/CD79b heterodimer also contributes to receptor internalization and antigen processing following BCR engagement. Regulation of CD79b phosphorylation, trafficking, and receptor association helps determine the duration and intensity of signaling responses. Disruption of these mechanisms can impair normal B-cell function or contribute to abnormal lymphocyte activation.
CD79b is expressed in many B-cell malignancies, including diffuse large B-cell lymphoma and other mature B-cell neoplasms. Mutations affecting the CD79B signaling region have been identified in subsets of activated B-cell-like diffuse large B-cell lymphoma and can contribute to altered BCR signaling. Its expression on malignant B cells has also made CD79b an important target for antibody-based therapeutic development. CD79b Antibody IGB/3170R supports investigations of B-cell receptor organization, immune signaling, lymphocyte differentiation, and the molecular mechanisms associated with B-cell malignancies.
CD79b is an essential component of the B-cell antigen receptor complex and an important marker for investigating B-cell development, immune signaling, and lymphoid malignancies.
Optimal dilution of the CD79b Antibody IGB/3170R / B-Cell Receptor CD79b Monoclonal Antibody should be determined by the researcher.
A recombinant human partial protein (amino acids 29-159) was used as the immunogen for this recombinant CD79b antibody.
Store the recombinant CD79b antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).
B29 antibody, B-cell antigen receptor complex-associated protein beta chain antibody, B-cell receptor-associated protein beta chain antibody, Immunoglobulin beta antibody, Ig-beta antibody, Ig beta antibody, CD79B protein antibody, B-cell antigen receptor CD79b antibody, B-cell receptor signaling protein CD79b antibody
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.